Women's Health · ContraceptiveRegulatory Approvalregulatorymid-term

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva9 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 12:31:21 AM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's ANDA219324 for Junel FE receiving Approval Pending status is significant as it signals a potential entry of a generic contraceptive into the market. This could disrupt pricing and market share dynamics for existing players in the women's health segment, necessitating proactive monitoring by pharma strategy teams. Regulatory context from FDA (FDA AP — LO JUNEL FE (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market dynamics as Teva approaches launch, which may affect pricing and market share of existing contraceptives. The strongest clinical anchor is Multidimensional Determinants of Functional Health In Women Aged 45-60 (ClinicalTrials.gov), moderate corpus alignment. In Women's Health · Contraceptive, 4 regulatory and 4 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate) (Humanexa Signals) — entity match (teva). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LO JUNEL FE (ORIG) (FDA). Entity match (teva); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. While the Approval Pending status indicates progress, the final approval decision will ultimately determine compliance and market readiness for Teva's product.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a generic contraceptive could lead to price competition, affecting revenue streams for established brands in the women's health market.
Upside for Teva may improve if Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should prepare for potential market dynamics as Teva approaches launch, which may affect pricing and market share of existing contraceptives.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval decision and subsequent market launch timeline for Teva's Junel FE.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LO JUNEL FE (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — COPAXONE (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Multidimensional Determinants of Functional Health In Women Aged 45-60
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Time to Healthy Lifestyle Habit Using Digital Health Tools in Adults at Risk of Diabetes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalshigh relevance
Entity match (teva)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in the relationship between mental symptoms in postmenopausal women and estrogen fluctuations.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva

Commercial impact

medium

The introduction of a generic contraceptive could lead to price competition, affecting revenue streams for established brands in the women's health market.

Regulatory impact

medium

While the Approval Pending status indicates progress, the final approval decision will ultimately determine compliance and market readiness for Teva's product.

What to watch

Monitor the final approval decision and subsequent market launch timeline for Teva's Junel FE.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.